Based on a phase 3 randomized clinical trial, durvalumab plus tremelimumab did not statistically significantly enhance OS or PFS versus chemotherapy in patients with PD-L1 tumor proportion score ≥ 25%, while there was improved OS or PFS in durvalumab plus tremelimumab than chemotherapy in patients with 25% of tumor cells expressing PD-L1. Here, CD274 is linked to neoplasm.